Peptides Similar to Orforglipron
Compare Orforglipron with related peptides and alternatives
📌TL;DR
- •4 similar peptides identified
- •Semaglutide: High - Both are selective GLP-1 receptor agonists used for weight management and type 2 diabetes
- •Tirzepatide: Moderate - Both are incretin-based therapies for weight management and diabetes, but with different receptor targets
Quick Comparison
| Peptide | Similarity | Key Differences |
|---|---|---|
| Orforglipron (current) | - | - |
| Semaglutide | High - Both are selective GLP-1 receptor agonists used for weight management and type 2 diabetes | Semaglutide is a 31-amino-acid injectable peptide (or oral with SNAC), while orforglipron is a non-peptide small molecule taken orally without food restrictions. Semaglutide is FDA-approved; orforglipron is investigational. |
| Tirzepatide | Moderate - Both are incretin-based therapies for weight management and diabetes, but with different receptor targets | Tirzepatide is a dual GIP/GLP-1 receptor agonist injectable peptide with greater weight loss efficacy (20.9%). Orforglipron is a selective GLP-1 agonist oral small molecule with more moderate weight loss. |
| Retatrutide | Moderate - Both are investigational incretin-based therapies for obesity | Retatrutide is a triple GIP/GLP-1/glucagon receptor agonist injectable peptide achieving up to 24.2% weight loss. Orforglipron is an oral selective GLP-1 agonist with 11.2% weight loss. |
| Mazdutide | Moderate - Both are investigational GLP-1-based therapies for obesity and diabetes | Mazdutide is a dual GLP-1/glucagon receptor agonist injectable peptide developed by Innovent/Lilly in China. Orforglipron is an oral selective GLP-1 agonist. |
SemaglutideHigh - Both are selective GLP-1 receptor agonists used for weight management and type 2 diabetes
Differences
Semaglutide is a 31-amino-acid injectable peptide (or oral with SNAC), while orforglipron is a non-peptide small molecule taken orally without food restrictions. Semaglutide is FDA-approved; orforglipron is investigational.
Advantages
Oral dosing without food restrictions, no injections needed, simpler manufacturing, potentially lower cost, high oral bioavailability (~79%)
Disadvantages
Lower weight loss in Phase 3 (11.2% vs 14.9%), no cardiovascular outcomes data, not yet approved, daily dosing vs weekly injection, no long-term market experience
TirzepatideModerate - Both are incretin-based therapies for weight management and diabetes, but with different receptor targets
Differences
Tirzepatide is a dual GIP/GLP-1 receptor agonist injectable peptide with greater weight loss efficacy (20.9%). Orforglipron is a selective GLP-1 agonist oral small molecule with more moderate weight loss.
Advantages
Oral non-injectable administration, no food restrictions, potentially lower cost due to small molecule manufacturing
Disadvantages
Substantially lower weight loss (11.2% vs 20.9%), selective GLP-1 only (no GIP agonism), not yet approved, no CV outcomes data
RetatrutideModerate - Both are investigational incretin-based therapies for obesity
Differences
Retatrutide is a triple GIP/GLP-1/glucagon receptor agonist injectable peptide achieving up to 24.2% weight loss. Orforglipron is an oral selective GLP-1 agonist with 11.2% weight loss.
Advantages
Oral administration, no injections, simpler drug profile with single receptor target
Disadvantages
Substantially lower weight loss efficacy, no glucagon receptor activity for hepatic fat reduction, both still investigational
MazdutideModerate - Both are investigational GLP-1-based therapies for obesity and diabetes
Differences
Mazdutide is a dual GLP-1/glucagon receptor agonist injectable peptide developed by Innovent/Lilly in China. Orforglipron is an oral selective GLP-1 agonist.
Advantages
Oral administration without food restrictions, single receptor target, potentially broader global development program
Disadvantages
Likely lower weight loss efficacy, no glucagon receptor component, daily oral dosing vs weekly injection
Peptides Related to Orforglipron#
Orforglipron occupies a unique position in the GLP-1 receptor agonist landscape as the most advanced non-peptide small molecule in this therapeutic class. While it targets the same receptor as semaglutide and other peptide-based GLP-1 agonists, its small-molecule nature offers distinct practical advantages (oral dosing, no food restrictions, simpler manufacturing) with the trade-off of somewhat lower weight loss efficacy compared to injectable competitors.
Semaglutide (Ozempic / Wegovy / Rybelsus)#
Semaglutide is the most directly comparable agent to orforglipron, as both are selective GLP-1 receptor agonists. The comparison is particularly relevant because semaglutide is available in both injectable (Ozempic, Wegovy) and oral (Rybelsus) formulations.
Efficacy comparison (cross-trial, not head-to-head):
- Semaglutide 2.4 mg SC (Wegovy): 14.9% weight loss at 68 weeks (STEP 1)
- Orforglipron 36 mg oral: 11.2% weight loss at 72 weeks (ATTAIN-1)
Key differentiators:
- Orforglipron is taken orally without food restrictions, while Rybelsus requires strict fasting
- Semaglutide has proven cardiovascular benefit (SELECT trial); orforglipron has no CV outcomes data
- Semaglutide has 7+ years of market experience; orforglipron is pre-approval
- Orforglipron's 79% oral bioavailability vs Rybelsus' 0.4-1% represents a fundamental pharmacokinetic advantage for oral delivery
| Parameter | Orforglipron | Semaglutide (Wegovy) | Semaglutide (Rybelsus) |
|---|---|---|---|
| Chemical type | Small molecule | Peptide | Peptide + SNAC |
| Route | Oral | SC injection | Oral |
| Dosing | Once daily | Once weekly | Once daily |
| Food restriction | None | N/A | Strict fasting |
| Weight loss | 11.2% | 14.9% | N/A (T2D indication) |
| CV outcomes | No data | Positive (SELECT) | No dedicated trial |
| FDA status | Investigational | Approved | Approved (T2D only) |
Tirzepatide (Mounjaro / Zepbound)#
Tirzepatide is a dual GIP/GLP-1 receptor agonist with the highest approved weight loss efficacy among available therapies. The comparison with orforglipron highlights the efficacy-convenience trade-off.
Efficacy comparison (cross-trial):
- Tirzepatide 15 mg SC: 20.9% weight loss at 72 weeks (SURMOUNT-1)
- Orforglipron 36 mg oral: 11.2% weight loss at 72 weeks (ATTAIN-1)
The nearly twofold difference in weight loss reflects both the dual receptor mechanism of tirzepatide and the higher doses achievable with injectable administration. However, orforglipron's oral convenience may be preferred by patients who decline injection therapy.
Retatrutide (LY3437943)#
Retatrutide, also developed by Eli Lilly, is a triple GIP/GLP-1/glucagon receptor agonist with the highest reported weight loss in Phase 2 (approximately 24.2%). Both agents are from the same company, suggesting Lilly is pursuing a portfolio strategy: orforglipron as an oral option for patients preferring pills, and retatrutide as a maximum-efficacy injectable option.
Other Oral GLP-1 Agonists in Development#
Orforglipron is not the only oral GLP-1 agonist in development. High-dose oral semaglutide (25 mg and 50 mg) is being studied for obesity, and several other oral small molecules targeting the GLP-1 receptor are in earlier development stages. The competitive landscape for oral anti-obesity medications is rapidly evolving.
Summary Comparison#
| Feature | Orforglipron | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|---|
| Chemical type | Small molecule | Peptide | Peptide | Peptide |
| Route | Oral | SC/Oral | SC | SC |
| Targets | GLP-1 | GLP-1 | GIP + GLP-1 | GIP + GLP-1 + Glucagon |
| Weight loss | 11.2% | 14.9% | 20.9% | ~24.2% |
| CV outcomes | No data | Positive | Pending | No data |
| FDA status | Phase 3 | Approved | Approved | Phase 3 |
| Dosing | Once daily oral | Weekly SC / daily oral | Weekly SC | Weekly SC |
Related Reading#
Frequently Asked Questions About Orforglipron
Explore Further
Disclaimer: For educational purposes only. Not medical advice. Read full disclaimer